MedTrace Logo

A Study of TY-1091 in Patients With Advanced Solid Tumors

NCT05675605 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2024-01-30

No results posted yet for this study

Summary

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Conditions

Interventions

DRUG

TY-1091

TY-1091(10mg,100mg) , once a day, oral administration Dose level is from 20mg to 800mg

Sponsors & Collaborators

  • TYK Medicines, Inc

    lead INDUSTRY

Principal Investigators

  • Jinlin Province Cancer Hosipital Cheng, Bachelor · Jilin Province Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-24
Primary Completion
2025-06-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05675605 on ClinicalTrials.gov